Pharmaceutical compositions of therapeutically active compounds

A method of treating advanced hematologic malignancies in a subject, each characterized by the presence of a mutant allele of IDH1, the method comprising administering to the subject in need thereof a pharmaceutical composition comprising:

• (a) a compound (S)—N—((S)-1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide (Compound 1), or a pharmaceutically acceptable salt thereof, as part of a solid dispersion;
• Form 1 of the Compound 1;
• or Form 2 of the Compound 1;
• and optionally (b) one or more pharmaceutically acceptable carrier(s).